Treatment of children and adolecents with cancer after the application of the guide lines for good clinical practice in 2004 and the evaluation of new measurements;Die Behandlungssituation in der pädiatrischen Onkologie und Hämatologie nach der Änderung des Arzneimittelgesetzes im Jahr 2004 und die Prüfung neuer Therapieoptionen

Klinische Padiatrie

Volumn 224, Issue 6, 2012, Pages 335-338

  Gobel U ^a   Korholz D ^b   Bernig, T ^b   Niehues, T ^b   Klingebiel, T ^b   Eggert, A ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER THERAPY; CLINICAL PRACTICE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRACTICE GUIDELINE; REVIEW;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DISEASE PROGRESSION; EVIDENCE-BASED MEDICINE; GERMANY; GUIDELINE ADHERENCE; HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE; INTERDISCIPLINARY COMMUNICATION; INTERNATIONAL COOPERATION; NATIONAL HEALTH PROGRAMS; NEOPLASM STAGING; NEOPLASMS; REGISTRIES; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 84868480591     PISSN: 03008630     EISSN: 14393824     Source Type: Journal    
DOI: 10.1055/s-0032-1327615     Document Type: Review

References (40)

1. Bien E., Balcerska A., Adamkiewicz-Drozynska E. et al. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkins lymphomas and acute lymphoblastic leukemias. Clin Biochem: 2009; 42 1144 1157
2. Bertrand J., McCuaig C., Dubois J. et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol: 2011; 28 649 654
3. Brämswig J. What is the future for fertility preservation in girls with cancer. Klin Padiatr: 2011; 223 110 112
4. Burkhardt B., Wößmann W. NHL-BFM registry 2012: Registry of the NHL-BFM study group for all subtypes of Non-Hodgkin Lymphoma diagnosed in children and adolescents. Supported by Deutsche Kinderkrebsstiftung
5. Calaminus G., Kiefeld B. Intrakranielle Keimzelltumoren - Zum Start der neuen SIOP CNC GCT II-Studie WIR. Die Zeitschrift der Deutschen-Leukämie- Forschungshilfe e.V. und der Deutschen Kinderkrebsstiftung Heft 2.12: 24-27
6. Calaminus G., Schneider D. T., Weissbach L. et al. Survival after an antiangiogenetic therapy and surgery in a wide spread growing teratoma originating from a testicular mixed malignant germ cell tumor. Klin Padiatr: 2009; 221 136 140
7. Corbacioglu S. Early phase clinical trials in pediatric Hematology and oncology. Klin Padiatr: 2012; 224 197 200
8. Chen C., Heusch A., Donner B. et al. Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents. Klin Padiatr: 2009; 221 162 166
9. Cheung N. K., Sowers R., Vickers A. J. et al. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol: 2006; 24 2885 2890 (Pubitemid 46630590)
10. Creutzig U., Henze G., Bielack S. et al. Krebserkrankungen im Kindesalter. Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Ärztebl: 2003; 100 A842 A852
11. Delgado D. C., Hank J. A., Kolesar J. et al. Genotypes of NK cell KIR receptors, their ligands, and Fcg receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res: 2010; 70 9554 9561
12. Dick T., Staege M. S., Reichmann G. et al. Manifestation of the MHC-unrestricted killing potential of a cytotoxic T cell clone requires activation in response to MHC-restricted self-presentation of antigen. J Immunol: 1993; 150 2575 2583 (Pubitemid 23127506)
13. Entwurf eines Gesetzes zur Weiterentwicklung der Krebsfrüherkennung und zur Qualitätssicherung durch klinische Krebsregister (Krebsfrüherkennungs- und -registergesetz - KFRG) http://www. bundesgesundheitsministerium.de/fileadmin/dateien/Downloads/Gesetze-und- Verordnungen/Laufende-Verfahren/K/Krebsregister/
14. Fischer M., Bijman M., Molin D. et al. Increased serum levels of interleukin-9 correlate to negative prognostic factors in Hodgkins lymphoma. Leukemia: 2003; 17 2513 2516 (Pubitemid 38072592)
15. Gause A., Roschansky V., Tschiersch A. et al. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkins lymphoma. Ann Oncol: 1991; 2 02 43 47
16. Grunewald TG P., Greulich N., Kontny U. et al. Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature. Klin Padiatr: 2012; 224 124 131
17. Kelley T. W., Pohlman B., Elson P. et al. The ratio of FOXP3+ regulatory T cells to granzyme B+ cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol: 2007; 128 958 965
18. Klingebiel T. Herausragende Wissenschaftspreise und Ehrungen für pädiatrische Onkologen. Klin Padiatr: 2012; 224 121 123
19. Klingebiel T., Creutzig U., Christaras A. et al. Meilensteine der Gesundheitspolitik und seltene Erkrankungen. Klin Padiatr: 2010; 222 121 123
20. Kluge R., Körholz D. Die Bedeutung des FDG-PET für die Stadieneinteilung und therapie des Hodgkin-Lymphoms im Kindesalter. Klin Padiatr: 2011; 223 315 319
21. Koscielniak E., Klingebiel T. CWS-Register SoTiSaR - CWS-2007-HR - A randomized phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localized high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults. (EudraCT-Nr: 2007-001478-10) Supported by Deutsche Kinderkrebsstiftung
22. Körholz D. EuroNet-PHL-C1 - First international Inter-Group Study for classical Hodgkins Lymphoma in Children and Adolescents. Supported by Deutsche Kinderkrebsstiftung
23. Krenn T., Fleischhack G., Moser O. et al. Bloodstream infections in paediatric cancer patients. Prospective Comparative stady I 2 university hospitals. Klin Padiatr: 2011; 223 335 340
24. Lawrenz B., Henes M., Neunhoeffer E. et al. Fertility preservation in girls and adolescents before chemotherapy and radiation - Review of the literature. Klin Padiatr: 2011; 223 126 130
25. Lindinger A., Schwedler G., Hense H-W. Prevalence of Congenital Heart Defects in Newborns in Germany: Results of the first registration year of the PAN Study (July 2006 to June 2007). Klin Padiatr: 2010; 222 321 326
26. Mintz-Hittner H. A., Kennedy K. A., Chuang A. Z. BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med: 2011; 364 603 615
27. Odri G. A., Dumoucel S., Picarda G. et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewings sarcoma patients. Cancer Res: 2010; 70 7610 7619
28. Purz S., Mauz-Körholz C., Körholz D. et al. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkins lymphoma. J Clin Oncol: 2011; 29 3523 3528
29. Reinhardt D., Reinhardt K., Neuhoff C. et al. GATA1-Mutations-assoziierte Leukämien bei Kindern mit Trisomie21-Mosaik. Klin Padiatr: 2012; 224 153 155
30. Reinmuth S., Liebeskind A. K., Wickmann L. et al. Having children after surviving cancer in childhood or adolescence - Results of a Berlin survey. Klin Padiatr: 2008; 220 159 165 (Pubitemid 351758158)
31. Rendtorff R., Hohmann C., Reinmuth S. et al. Hormone and sperm analyses after chemo- and radiotherapy in childhood and adolescence. Klin Padiatr: 2010; 222 145 149
32. Schlegel N., Bardet V., Kenet G. et al. Diagnostic and therapeutic considerations on inherited platelet disorders in neonates and children. Klin Padiatr: 2010; 222 209 214
33. Staege M. S., Hattenhorst U. E., Neumann U. E. et al. DNA-microarrays as tools for the identification of tumor specific gene expression profiles: applications in tumor biology, diagnosis and therapy. Klin Padiatr: 2003; 215 135 139
34. Steidl C., Lee T., Shah S. P. et al. Tumor-associated macrophages and survival in classic Hodgkins lymphoma. N Engl J Med: 2010; 362 875 885
35. Streif W., Knöfler R., Eberl W. Inherited disorders of platelet function in paediatric clinical practice: a diagnostic challenge. Klin Padiatr: 2010; 222 203 208
36. Thiele K. P., Rheineberger P. Unmöglich" gibt es nicht. Dtsch Ärztebl: 2003; 100 A1044 A1046
37. Topp M. S., Kufer P., Gökbuget N. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol: 2011; 29 2493 2498
38. Verordnung über die Anwendung der Guten Klinischen Praxis bei der Durchführung von klinischen Prüfungen mit Arzneimitteln zur Anwendung am Menschen (GCP-V). DCP-Verordnung vom 9. August 2004 (BGBL. I S. 2081), zuletzt geändert durch Artikel 4 der Verordnung vom 3. November 2006 (BGBL. I S. 2523). Bundesministerium der Justiz 2006.
39. Younes A., Bartlett N. L., Leonard J. P. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med: 2010; 363 1812 1821
40. Zwölftes Gesetz zur Änderung des Arzneimittelgesetzes vom 30. Juli 2004. BGBl I 05. August 2004. Nr. 41, 2031-2053